A phase-I open-label study of the absorption, metabolism, and excretion of (14C)-ramelteon (TAK-375) following a single oral dose in healthy male subjects

被引：0
|
作者：
Hibberd, M
Stevenson, SJ
机构：
[1] Takeda Europe Res & Dev Ctr Ltd, London, England
[2] Covance Clin Res Unit Ltd, Leeds, W Yorkshire, England
来源：
SLEEP | 2004年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
121
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [31] ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION OF TROPIFEXOR, A POTENT FXR AGONIST FOR THE TREATMENT OF NASH, FOLLOWING A SINGLE ORAL 1 MG DOSE OF [14C]TROPIFEXOR IN HEALTHY MALE SUBJECTS
    Wang-Lakshman, Lydia
    Miao, Zhuang
    Gu, Jessie
    Choudhury, Subhajit
    McNamara, Elizabeth
    Walles, Markus
    Woessner, Ralph
    Camenisch, Gian
    Chen, Jin
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S76 - S76
  • [32] Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects
    Johnson, Theodore R.
    Goulet, Lance
    Smith, Evan B.
    Yamazaki, Shinji
    Walker, Gregory S.
    Tan, Weiwei
    Li, Chunze
    Ni, Yao
    Bedarida, Gabriella
    Brega, Nicoletta
    Dalvie, Deepak
    Smith, Bill J.
    DRUG METABOLISM REVIEWS, 2011, 43 : 77 - 77
  • [33] Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects
    Johnson, Theodore R.
    Tan, Weiwei
    Goulet, Lance
    Smith, Evan B.
    Yamazaki, Shinji
    Walker, Gregory S.
    O'Gorman, Melissa T.
    Bedarida, Gabriella
    Zou, Helen Y.
    Christensen, James G.
    Nguyen, Leslie N.
    Shen, Zhongzhou
    Dalvie, Deepak
    Bello, Akintunde
    Smith, Bill J.
    XENOBIOTICA, 2015, 45 (01) : 45 - 59
  • [34] A PHASE I, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE EXCRETION AND MASS BALANCE, PHARMACOKINETICS, AND METABOLISM OF [14C]-INFIGRATINIB (BGJ398) IN HEALTHY ADULT VOLUNTEERS.
    Reyes, M.
    Zamora, C.
    Andrews, S.
    Guptha, S.
    Roupe, K.
    Panicucci, R.
    Moran, S.
    Martin, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S57 - S57
  • [35] THE MASS BALANCE RECOVERY, ABSORPTION, METABOLISM, AND EXCRETION OF [14C]-ORVEPITANT IN HEALTHY MALE SUBJECTS AFTER ORAL DOSING: RADIOSYNTHESIS OF [14C]-ORVEPITANT
    Carver, David
    Craig, Jo
    Lawrence, Ron
    Pawsey, Steve
    Cousins, Peggy
    Martos, Jose
    Shaw, Iain
    DRUG METABOLISM AND PHARMACOKINETICS, 2024, 55
  • [36] Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans
    Yihua E. Ye
    Caroline N. Woodward
    Narayana I. Narasimhan
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 507 - 518
  • [37] Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans
    Ye, Yihua E.
    Woodward, Caroline N.
    Narasimhan, Narayana I.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 507 - 518
  • [38] Absorption, Metabolism, and Excretion of [14C]-Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open-Label, Mass-Balance Study
    Cotreau, Monette M.
    Hale, Christine L.
    Jacobson, Lindsey
    Oelke, Claudine S.
    Strahs, Andrew L.
    Kochan, Robert G.
    Sanga, Madhu
    Slichenmyer, William
    Vargo, Dennis L.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2012, 1 (03): : 102 - 109
  • [39] Pharmacokinetics, metabolism and excretion of 14C-ragaglitazar after a single oral dose to healthy male subjects
    Vanggaard, J
    Wassmann, O
    Andersen, MP
    Skrumsager, BK
    DIABETES, 2002, 51 : A490 - A490
  • [40] 14C-ragaglitazar:: pharmacokinetics, metabolism and excretion after a single oral dose to healthy male subjects
    Vanggaard, J
    Wassmann, O
    Andersen, MP
    Skrumsager, BK
    DIABETOLOGIA, 2002, 45 : A232 - A232
12345